Who are RSV Polyclonal Immunoglobulin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anthrax Immune Globulin, human histaglobulin, IgY.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rsv-polyclonal-immunoglobulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

RSV Polyclonal Immunoglobulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RSV Polyclonal Immunoglobulin (RSV Polyclonal Immunoglobulin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal immunoglobulin. Area: Immunology / Infectious Disease.

marketed Polyclonal immunoglobulin Respiratory syncytial virus (RSV) surface proteins Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

RSV Polyclonal Immunoglobulin (RSV Polyclonal Immunoglobulin) — National Institute of Allergy and Infectious Diseases (NIAID). RSV polyclonal immunoglobulin provides passive immunity by supplying antibodies that bind to respiratory syncytial virus and neutralize its infectivity.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RSV Polyclonal Immunoglobulin TARGET	RSV Polyclonal Immunoglobulin	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Polyclonal immunoglobulin	Respiratory syncytial virus (RSV) surface proteins
Anthrax Immune Globulin	Anthrax Immune Globulin	National Institutes of Health Clinical Center (CC)	marketed	Polyclonal immunoglobulin; passive immunotherapy	Anthrax protective antigen (PA); anthrax lethal factor (LF)
human histaglobulin	human histaglobulin	Hangzhou Grand Biologic Pharmaceutical, Inc.	marketed	Polyclonal immunoglobulin; antihistamine immunoglobulin	Histamine and mast cell stabilization
IgY	IgY	Mukoviszidose Institut gGmbH	phase 3	Polyclonal immunoglobulin Y (IgY) therapeutic	Pseudomonas aeruginosa lipopolysaccharide and surface antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal immunoglobulin class)

National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RSV Polyclonal Immunoglobulin — Competitive Intelligence Brief. https://druglandscape.com/ci/rsv-polyclonal-immunoglobulin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing